| Human renal function maturation: a quantitative description using weight and postmenstrual age MM Rhodin, BJ Anderson, AM Peters, MG Coulthard, B Wilkins, M Cole, ... Pediatric nephrology 24, 67-76, 2009 | 492 | 2009 |
| Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised … B Seddon, SJ Strauss, J Whelan, M Leahy, PJ Woll, F Cowie, ... The lancet oncology 18 (10), 1397-1410, 2017 | 407 | 2017 |
| Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies N Widmer, C Bardin, E Chatelut, A Paci, J Beijnen, D Levêque, G Veal, ... European journal of cancer 50 (12), 2020-2036, 2014 | 338 | 2014 |
| Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics A Paci, G Veal, C Bardin, D Levêque, N Widmer, J Beijnen, A Astier, ... European journal of cancer 50 (12), 2010-2019, 2014 | 281 | 2014 |
| Sodium thiosulfate for protection from cisplatin-induced hearing loss PR Brock, R Maibach, M Childs, K Rajput, D Roebuck, MJ Sullivan, ... New England Journal of Medicine 378 (25), 2376-2385, 2018 | 275 | 2018 |
| Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells JL Armstrong, R Flockhart, GJ Veal, PE Lovat, CPF Redfern Journal of Biological Chemistry 285 (9), 6091-6100, 2010 | 181 | 2010 |
| Metabolism of zidovudine GJ Veal, DJ Back General pharmacology: The vascular system 26 (7), 1469-1475, 1995 | 136 | 1995 |
| Therapeutic drug monitoring in cancer–are we missing a trick? C Bardin, G Veal, A Paci, E Chatelut, A Astier, D Levêque, N Widmer, ... European journal of cancer 50 (12), 2005-2009, 2014 | 134 | 2014 |
| Clinical pharmacology in the adolescent oncology patient GJ Veal, CM Hartford, CF Stewart Journal of clinical oncology 28 (32), 4790, 2010 | 120 | 2010 |
| The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites MG Barry, SH Khoo, GJ Veal, PG Hoggard, SE Gibbons, EGL Wilkins, ... Aids 10 (12), 1361-1367, 1996 | 119 | 1996 |
| Oxazaphosphorines: new therapeutic strategies for an old class of drugs B Giraud, G Hebert, A Deroussent, GJ Veal, G Vassal, A Paci Expert opinion on drug metabolism & toxicology 6 (8), 919-938, 2010 | 106 | 2010 |
| Lamivudine (3TC) phosphorylation and drug interactions in vitro S Kewn, GJ Veal, PG Hoggard, MG Barry, DJ Back Biochemical pharmacology 54 (5), 589-595, 1997 | 102 | 1997 |
| A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin GJ Veal, MJ Griffin, E Price, A Parry, GS Dick, MA Little, SM Yule, ... British journal of cancer 84 (8), 1029-1035, 2001 | 98 | 2001 |
| The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation N Martinez-Soria, L McKenzie, J Draper, A Ptasinska, H Issa, S Potluri, ... Cancer Cell 34 (4), 626-642. e8, 2018 | 96 | 2018 |
| Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers M Barry, M Wild, G Veal, D Back, A Breckenridge, R Fox, N Beeching, ... Aids 8 (8), F1-1024, 1994 | 79 | 1994 |
| 13-cis retinoic acid and isomerisation in paediatric oncology—is changing shape the key to success? JL Armstrong, CPF Redfern, GJ Veal Biochemical pharmacology 69 (9), 1299-1306, 2005 | 73 | 2005 |
| Clinical and cellular pharmacology in relation to solid tumours of childhood EJ Estlin, GJ Veal Cancer treatment reviews 29 (4), 253-273, 2003 | 73 | 2003 |
| Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study GJ Veal, M Cole, J Errington, A Parry, J Hale, ADJ Pearson, K Howe, ... Clinical cancer research 11 (16), 5893-5899, 2005 | 68 | 2005 |
| Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the … GJ Veal, L Nguyen, A Paci, M Riggi, M Amiel, D Valteau-Couanet, P Brock, ... European Journal of Cancer 48 (16), 3063-3072, 2012 | 63 | 2012 |
| A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. SER Halford, P Jones, S Wedge, S Hirschberg, S Katugampola, G Veal, ... Journal of Clinical Oncology 35 (15_suppl), 2516-2516, 2017 | 62 | 2017 |
